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Abstract
Background: Chemotherapy plays a role in the treatment of endometrioid endometrial cancer (EEC); however,
tumor grade may affect response. Our objective was to evaluate associations between tumor grade and in vitro
chemoresponse.
Methods: We conducted an analysis of primary tumor samples from women with EEC undergoing in vitro
chemoresponse testing. Results were classified as sensitive (S), intermediate (I), or resistant (R) to each drug tested.
Correlations between tumor grade and response were examined.
Results: Data was collected from 159 patients: 28 with grade 1 (18%), 52 with grade 2 (32%), and 79 (50%) with
grade 3 tumors. Median age of patients was 62 (range 31–92). Most patients were Caucasian (83%) with advanced
disease (Stage III: 50.9%; Stage IV: 13.2%). Overall chemoresponse was similar across all grades. Fifty percent, 56 and
51% for grade 1, 2, and 3 tumors, respectively, demonstrated S results to at least 1 agent. There was no association
between grade and in vitro response to chemotherapy agents (p > 0.05) except a marginal association between
grade and doxorubicin response (p = 0.08). Grade 1 and 2 cancers were more likely to demonstrate R results for
doxorubicin compared to grade 3 cancers (G1: 19% vs G2: 25% vs G3: 8%; p = 0.08). In a subset tested for all 7
agents, only one patient tumor was pan-R and 4 were pan-S.
Conclusions: Based on our data, grades 1–3 EEC have similar in vitro chemoresponse. These findings suggest that
chemotherapy may be useful in advanced low grade EECs, but further clinical correlation is needed.
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Background
Endometrial cancer (EC) is the most common gyneco-
logic malignancy, with nearly 55,000 new cases and
more than 10,000 deaths predicted for 2015 [1]. While
5 year survival trends have improved for other gyneco-
logic malignancies, the survival rate for patients diag-
nosed with EC between 2004 and 2010 is lower than
that of patients diagnosed between 1975 and 1977 (83
vs. 87% p = <0.05) [1]. Undoubtedly, many factors
account for this trend; however it is yet unknown if
chemoresistance plays an important role.
The mechanism underlying chemoresistance in EC is
uncertain, however current dogma suggests that low
grade Type I endometrioid endometrial cancers (EEC)
are less likely to respond to chemotherapy. Type I tu-
mors represent the majority of sporadic EC, character-
ized predominantly by endometrioid histology and
expression of estrogen and/or progesterone receptors
[2]. In contrast, Type II EC is less common and often of
serous or clear cell histology, arising in atrophic endo-
metrium, rather than estrogen excess [3]. There is
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conflicting data regarding chemotherapy response and
tumor grade and histology in endometrial cancers.
Response rate (RR) to chemotherapy was not signifi-
cantly different between endometrioid (44%), clear cell
(32%) and serous tumors (44%) in a pooled analysis of
patients with advanced or recurrent EC treated on 1 of 4
GOG trials (GOG 107, GOG 139, GOG 163, GOG 177)
(clear cell p = 0.13; serous p = 0.99) [4]. In a subgroup
analysis of over 600 patients with endometrioid histology
alone enrolled in these same 4 GOG trials, grade 3 tu-
mors had an estimated odds of response of approxi-
mately 1.5 times that of grade 1 tumors, although these
results were not statistically significant (p = 0.09) [4].
However, these two analyses were based on a retrospect-
ive assessment of investigator-determined response
which may be prone to subjective assessment and error.
We previously explored the association between tumor
grade and cytotoxic treatment response in patients with
advanced or recurrent EEC (N = 91). Contrary to expec-
tations, grade 2 cancers were more likely to respond to
all types of chemotherapy (72 vs 43% p = 0.02) and to
carboplatin/paclitaxel doublets (72 vs 41% p = 0.02)
compared to grade 3 cancers [5]. However, this study
was limited by lack of central pathology review, small
sample size, and paucity of patients with grade 1 ECC.
Given the contradictory data and limitations of prior
studies, we explored in vitro chemoresponse profiles to
obtain insight into the relationship between chemothera-
peutic anti-tumor activity and grade in EEC specimens
from women enrolled in observational studies.
Methods
The study population included women with endome-
trioid endometrial cancer whose primary cancer speci-
mens were submitted for in vitro chemoresponse assay
testing on prospectively-accrued observational studies
between 2006 and 2010. These were longitudinal, obser-
vational multi-center studies examining the outcomes
associated with chemosensitivity assays in women with
gynecologic malignancies. Participants had not received
chemotherapy prior to specimen collection. Tumor grades
were assigned by the institutions submitting the speci-
mens for testing. Assays were conducted for up to 7 cyto-
toxic agents including carboplatin, cisplatin, doxorubicin,
paclitaxel, docetaxel, gemcitabine, and topotecan.
Details regarding the particular chemoresponse assay
used in this study (ChemoFx®, Helomics Corporation,
Pittsburgh, PA) have been described elsewhere [6, 7].
Assay preparation included an immunocytochemistry
step to aid in the confirmation that cells were of epi-
thelial, rather than stromal, origin. All cultures re-
quired a majority of epithelial cells to proceed to
chemoresponse testing. A board-certified pathologist
assessed cell morphology.
Inhibition of tumor growth was measured at several
serially-diluted concentrations of each cytotoxic agent
tested. For each drug, the area under the dose–response
curve (AUC) was calculated. Greater sensitivity to the
therapy tested was indicated by a smaller AUC. Using
established criteria, tumor chemoresponse was classified
using the in vitro AUC score into one of three categor-
ies: sensitive (S), intermediate sensitive (I), or resistant
(R). The in vitro tumor response rate (RR) for each agent
was then defined as the proportion of patients with tu-
mors testing either S or I for that agent.
The primary endpoint of this ancillary study was to as-
sess the association between tumor grade and in vitro
chemoresponse assay results in EEC. Patient demo-
graphics were also collected, including age and stage at
diagnosis. Correlations of tumor grade with assay results
were examined using Cochran-Armitage test for trend
using SAS version 9.4 (SAS Institute, Cary, NC).
Results
A total of 159 patients were included for this analysis.
Twenty-eight patients had grade 1 (18%), 52 had grade 2
(32%), and 79 (50%) had grade 3 tumors. The median
age of patients was 62 (range 31–92). Most patients were
Caucasian (83%) and had advanced stage disease (Stage
III: 50.9%; Stage IV: 13.2%) at diagnosis [Table 1].
As mentioned previously, the chemotherapeutic agents
tested in this assay included carboplatin, cisplatin, doxo-
rubicin, and paclitaxel, which are commonly used in EC.
In addition, other cytotoxics incorporated in the panel









No. (%) No. (%) No. (%) No. (%)
Age (years)
Median (Range) 63.5 (42–92) 62 (32–87) 62 (31–89) 62 (31–92)
< 50 2 (7.1) 8 (15.4) 9 (11.4) 19 (11.9)
50–64 13 (46.4) 22 (42.3) 36 (45.6) 71 (44.7)
65–74 8 (28.6) 14 (26.9) 24 (30.4) 46 (28.9)
≥ 75 5 (17.9) 8 (15.4) 10 (12.7) 23 (14.5)
Race
White 24 (85.7) 45 (86.5) 63 (79.7) 132 (83)
Black 1 (3.6) 4 (7.7) 12 (15.2) 17 (10.7)
Other 3 (10.7) 3 (5.8) 4 (5.1) 10 (6.3)
FIGO Stage
I 11 (39.3) 8 (15.4) 21 (26.6) 40 (25.2)
II 0 (0.0) 8 (15.4) 7 (8.9) 15 (9.4)
III 15 (53.6) 28 (53.8) 38 (48.1) 81 (50.9)
IV 2 (7.1) 6 (11.5) 13 (16.5) 21 (13.2)
Unknown 0 (0.0) 2 (3.8) 0 (0.0) 2 (1.3)
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were evaluated including docetaxel, gemcitabine, and
topotecan. Not all patients had their tumors tested for all
7 cytotoxic agents. Assay results were available for the fol-
lowing cytotoxic agents stratified by grade 1, 2, and 3: car-
boplatin (25/28[89%], 41/52[79%], 66/79[84%]), paclitaxel
(24/28[86%], 40/52[77%], 65/79[82%]), doxorubicin (27/
28[96%], 48/52[92%], 77/79[97%]), cisplatin (24/28[86%],
43/52[83%], 67/79[85%]), docetaxel (19/28[68%], 35/
52[67%], 61/79[77%]), gemcitabine (14/28[50%], 26/
52[50%], 45/79[56%]), and topotecan (22/28[71%], 41/
52[79%], 61/79[77%]) [Table 2].
The number of R results, defined as responses that were
neither S nor I, was similar across grades. Twenty seven
percent, 21, and 17% for grade 1, 2, and 3 tumors, respect-
ively, demonstrated resistant chemoresponse results for
any of the agents tested. There was no association be-
tween tumor grade and in vitro response to various
chemotherapy agents (p > 0.05) other than a marginal
association between grade and response to doxorubicin
(p = 0.08) (Table 2). Specifically, grade 1 and 2 cancers
were more likely to demonstrate R assay results for
doxorubicin compared to grade 3 cancers (G1: 18% vs
G2: 25% vs G3: 8%; p = 0.08).
Ten of 28 (36%) grade 1, 21/52 (38%) grade 2, and 33/
79 (42%) grade 3 tumors were tested for all 7 cytotoxic
agents (Fig. 1). Of those grade 1 tumors tested for all 7
cytotoxic agents, 6/10 (60%) were pan-sensitive (defined
as S + I), and none were pan-resistant. Of the 21 grade 2
tumors tested for all 7 agents, 10 (47.6%) were pan-
sensitive and 1 (5%) pan-resistant. Similarly, 19 of 33
(57.6%) grade 3 tumors were pan-sensitive while none
were pan-resistant. When examining the entire cohort
of tumors, 14/ 28 (50%) grade 1 tumors exhibited a sen-
sitive (S only) chemoresponse assay to at least 1 agent.
Similarly, 29/52 (56%) of grade 2 tumors and 40/79
(51%) grade 3 tumors also showed in vitro sensitivity to
at least one cytotoxic agent. If S + I responses are con-
sidered, these RRs increase to 73, 79 and 83% for grades
1, 2 and 3 tumors, respectively.
Discussion
Our data suggests there is no difference in in vitro che-
moresponse among EECs of various grades. When
stratified by tumor grade, RRs were similar for 7 che-
motherapeutic agents with the exception of doxorubi-
cin, where grade 3 tumors exhibited a non-significant
increased RR (92% (S + I)) compared to grade 1 (81%)
and grade 2 (75%) tumors. Overall our results are simi-
lar to the clinical findings reported by McMeekin and
colleagues examining the relationship between tumor
histology and chemotherapeutic response in 4 GOG
endometrial cancer trials (GOG#107, GOG#139,
GOG#163, GOG#177). To date, this GOG ancillary
analysis is the largest study to examine the association
between tumor grade and chemotherapy response in
EEC [4]. These trials encompassed both advanced and
recurrent EC treated with a variety of cytotoxic agents,
including doxorubicin, a doxorubicin/cisplatin doublet,
a doxorubicin/paclitaxel doublet, and a doxorubicin/
cisplatin/paclitaxel triplet administered in various inter-
vals and doses [8–11]. The majority of patients in-
cluded in these studies had also received prior radiation
therapy. In a subgroup analysis of over 600 patients
with endometrioid histology only, there was no differ-
ence in response of grade 3 versus grade 1 tumors (p =
0.09). Furthermore, tumor grade was not associated
with progression free survival (PFS) or overall survival
[4]. This may be due, in part, to the fact that patients
had advanced or recurrent disease associated with a
Table 2 In Vitro Tumor Responses to Seven Drugs
Assay Resultb
Drug Tumor Grade No. patients R (%) I (%) S (%) P valuea
Carboplatin .928
1 25 28.0 40.0 32.0
2 41 24.4 39.0 36.6
3 66 19.7 53.0 27.3
Cisplatin .322
1 24 29.2 41.7 29.2
2 43 18.6 55.8 25.6
3 67 13.4 58.2 28.4
Docetaxel .812
1 19 26.3 42.1 31.6
2 35 8.6 54.3 37.1
3 61 18.0 47.5 34.4
Doxorubicin .080
1 27 18.5 55.6 25.9
2 48 25.0 56.3 18.8
3 77 7.8 61.0 32.2
Gemcitabine .238
1 14 28.6 28.6 42.9
2 26 30.8 23.1 46.2
3 45 22.2 62.2 15.6
Paclitaxel .670
1 24 33.3 33.3 33.3
2 40 15.0 37.5 47.5
3 65 15.4 53.9 30.8
Topotecan .861
1 22 27.3 45.5 27.3
2 41 24.4 48.8 26.8
3 61 23.0 50.8 26.2
aCorrelation of tumor grade with assay result examined by
Cochran-Armitage test
bR resistant, I intermediately sensitive, S sensitive
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poor prognosis, limiting the ability to detect differences
in subgroups. While there was heterogeneity among
these various studies, the strength of the ancillary ana-
lysis of the GOG trials is the uniform delivery of ther-
apy in a prospective clinical trial setting, and pathologic
confirmation of tumor grade and histology required for
enrollment.
The correlation between in vitro chemoresponse &
tumor grade, as well as the correct definition of this re-
sponse (S + I vs S) in women with EC is unknown. We
compared our in vitro chemotherapy response to the
RR reported in the literature for combination carbopla-
tin/paclitaxel (CT) or cisplatin/doxorubicin/paclitaxel
(TAP), the current standard of care therapy for ad-
vanced or recurrent EC. In our study, RRs based on in
vitro chemotherapy response defined as S + I, were
noted for the following agents: carboplatin, 77%; pacli-
taxel, 81%; cisplatin, 82%; and doxorubicin, 85%. These
in vitro chemotherapy RRs are nearly twice the RRs re-
ported in the 4 GOG trials studied by McMeekin et al.
[4] However, when only S results are considered (carbo-
platin, 31%; paclitaxel, 36%; cisplatin, 28%; doxorubicin:
26%), our in vitro results are similar to those reported
in several small phase II trials evaluating the use of sin-
gle agents in chemo naïve patients with EC. For ex-
ample, 20% of women with chemo naïve advanced or
recurrent EC receiving single agent cisplatin achieved a
response [12], compared to a 28% in vitro response in
our analysis. Furthermore, our in vitro results were
nearly identical to those seen with paclitaxel (14.3%
CR, 21.4% PR) in GOG-86O and doxorubicin (RR 25%)
in GOG-107 [10, 13]. No in vitro doublet assays were
performed for comparison with in vivo studies. Com-
parisons between the populations in these prior studies
and our results are limited due to different dosing
schedules as well as the in vitro vs. in vivo differences.
However, the results suggest that in vitro studies may
be applicable in predicting tumor response in vivo.
Data from epithelial ovarian cancer (EOC) specimens
have compared in vitro assay response to clinical out-
comes. Krivak and colleagues reported that in vitro assay
resistance to carboplatin is associated with decreased
PFS in women with advanced-stage EOC treated with
platinum based therapy. Specifically, women whose
tumor specimens demonstrated in vitro platinum resist-
ance were at higher risk for disease progression com-
pared to those with sensitive or intermediate sensitive
assay results (median PFS: 11.8 vs 16.6 months, respect-
ively, P < .001) [6]. In addition, our group compared in
vitro assay response between Type I and Type II EOC
and found that, despite the dogmatic belief that Type I
EOC are chemoresistant, the majority (86%) of Type I
tumors were chemosensitive to at least one cytotoxic
agent and 35.7% were pan-S to all 7 agents tested [14].
Multi-drug resistance was twice as likely in women with
Type I EOC compared to Type II EOC (pan-R, 14.3 vs.
6.8% (p = 0.268); pan-S, 35.7 vs. 51.2% (p = 0.183)), but
did not reach statistical significance. Similarly, in our
analysis in EC, 20% of grade 1 tumors were pan-
sensitive. None of the grade 1 ECs were resistant to the
7 agents included in the cytotoxic panel, indicating that
chemotherapy may be useful in the treatment of grade 1
advanced or recurrent disease. These recent studies
demonstrate the clinical validity and utility of in vitro
Fig. 1 Distribution of assay results across seven single agent treatments. Patients (n = 64) were categorized based on response to carboplatin,
cisplatin, doxorubicin, gemcitabine, paclitaxel, docetaxel, and topotecan. Tumors were either resistant to all drugs (S0), or sensitive (S + I) from
anywhere from one (S1) agent to all 7 agents (S7). Sixty percent of grade 1 tumors were pan-sensitive (S7) vs 47.6 and 57.6% of grades 2 and 3
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chemotherapy assays to direct therapy. Continued evalu-
ation could further support the role of this test in clin-
ical practice, especially given the interest in precision
and personalized medicine.
Understanding the intricacies of molecular differences
in EC histologies may be fundamental in directing tar-
geted therapies. Data from The Cancer Genome Atlas
(TCGA) have identified molecular signatures that may
account for heterogeneity in treatment response for
endometrioid endometrial tumors. While only a small
percentage of grade 1 and 2 EECs have genetic finger-
prints similar to serous endometrial cancers, almost 25%
of grade 3 EECs possess signatures closely related to
these more aggressive tumors [15]. This data supports
the possibility of including grade 3 EECs with other
Type II EECs. However, it is uncertain if these molecular
signatures are associated with or can differentially pre-
dict response to chemotherapy in endometrioid cancers
and Type II cancers. Additional analyses into molecular
fingerprints of these malignancies have also helped to
characterize pathways that may be involved in low grade,
yet aggressive EEC in young women. While the PI3K
pathway is a source of frequent mutations in EEC, differ-
ential expression of hotspot mutations have been noted
in microsatellite stable vs. instable endometrial tumors
[16]. As we learn more about the intricacies of the can-
cer genome, it is apparent that histology and tumor
grade may not be the only factors that determine the be-
havior of these endometrial malignancies.
Limitations of this study include the lack of size
equivalence between the tumor grade cohorts (namely,
fewer tumors in the grade 1 cohort). In addition, not all
tumors underwent chemosensitivity testing to all 7
agents as physicians could choose which drugs to sub-
mit, thus introducing a selection bias. Strengths of this
study include the prospective collection of data that was
routinely and comprehensively monitored, as well as the
uniform preparation and performance of the chemosen-
sitivity assay. Less than 20% of submitted samples fail
the assay due to insufficient cell growth in culture or
contamination. We were unable to assess the association
between in vitro response results and clinical RR and
survival outcomes due to limited clinical data.
Conclusion
Based on our results, there does not appear to be an as-
sociation between tumor grade and in vitro chemore-
sponse assay results. Specifically low grade EECs are not
more likely to have resistant assay results compared to
higher grade EECs. In addition, 50% of grade 1 EECs
demonstrated in vitro sensitivity to at least one cytotoxic
therapy, suggesting that chemotherapy may be useful in
advanced low grade EECs. However, further clinical cor-
relation is needed to assess assay sensitivity/resistance to
in vivo response and clinical outcomes to determine if
chemoresponse assays may be useful to direct therapy in
women with endometrioid endometrial cancer.
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